HONG KONG, China, 31 March 2026 – MGI Tech Co Ltd (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, BiomOrgan Limited (“BiomOrgan”), a Hong Kong-based life science company, and InnoHK Centre for Virology, Vaccinology and Therapeutics Limited (“CVVT”), today announced a strategic collaboration to launch PDOHub™ HK, Asia’s first integrated organoid-based precision medicine centre.

The agreement was formalised during a signing ceremony at Hong Kong Science Park. The collaboration seeks to combine the respective strengths, expertise and resources of all three parties to establish and operate a dedicated centre for patient-derived organoid (PDO)-based technologies that advance precision medicine, clinical decision support and translational research across multiple disease areas. PDOHub™ HK will serve as a central hub for developing and scaling organoid-based applications that connect cutting-edge science with clinical practice. By enabling patient-specific insights, the initiative empowers researchers and healthcare partners to accelerate discovery and refine therapeutic strategies across infectious diseases, oncology and other emerging health challenges—positioning PDOHub™ HK as a leading organoid-driven precision medicine centre in Asia.

Industry–Academic–Research Collaboration

Under the collaboration, BiomOrgan and CVVT will provide the scientific foundation for PDOHub™ HK’s operations. BiomOrgan leverages its patented platform and proprietary know-how to drive oncology PDO services, while CVVT contributes its patented platform for infectious disease applications. Together, they will lead business development and market engagement to expand PDOHub™ HK’s presence and impact across local and international markets.

BiomOrgan is committed to supporting eligible cancer patients in accessing the tumour organoid drug sensitivity test, an in vitro laboratory assessment that evaluates how patient-derived tumour organoids respond to different therapeutic options. The programme provides clinicians with additional scientific insights that may be considered alongside other clinical inputs. Access is available for multiple cancer types, including oesophageal, stomach, colorectal, triple-negative breast and lung cancers. Eligibility will be assessed in collaboration with participating clinicians to ensure equitable access.

MGI will support the initiative by co-developing automation systems for organoid-based antibody testing and providing high-throughput sequencing platforms for patient-derived organoids. These technical contributions will enhance PDOHub™ HK’s ability to generate high-quality, data-driven insights and expand its capacity for advanced organoid-based research and innovation.

The partnership also extends into translational infectious disease research, combining BiomOrgan and CVVT’s patented organoid platforms for screening antiviral drugs and antibodies, alongside vaccine development supported by MGI’s automation technologies. This joint effort will establish faster, scalable laboratory systems to study virus–host interactions and evaluate the efficacy of antiviral drugs and vaccines, strengthening Hong Kong’s pandemic preparedness through rapid scientific insights to improve public health.

Dr Zhang Yong, CEO of BiomOrgan Limited, said:
“This collaboration marks a major step forward in strengthening Hong Kong’s position in organoid innovation and precision medicine. At BiomOrgan, we are dedicated to translating patient-derived organoid technologies into real-world solutions that drive scientific progress and public benefit. By enhancing our oncology and infectious disease platforms, PDOHub™ HK will deliver faster, more actionable insights that support data-driven decision-making across research, healthcare and public health.”

Professor Zhou Jie, Founder of BiomOrgan and Principal Investigator at CVVT, added:
“The launch of PDOHub™ HK represents a turning point in our vision to translate cutting-edge academic research into clinical impact. Through the integration of MGI’s automation and sequencing strengths with our organoid platforms, we are opening new possibilities in precision medicine and advancing strategies to combat infectious diseases.”

Duncan Yu, President of MGI, said:
“At MGI, we are committed to empowering the global life science community with advanced, user-friendly, intelligent tools. This collaboration underscores our commitment to advancing global health through cutting-edge technology and scientific innovation. By integrating our sequencing platforms and intelligent laboratory workflows into PDOHub™ HK, we are establishing a standardised, high-quality framework to make precision oncology more accessible. Together with BiomOrgan and CVVT, we aim to accelerate the translation of organoid-based research, driving biomedical innovation across Hong Kong, the Greater Bay Area and the wider Asia-Pacific region.”

About BiomOrgan Limited

BiomOrgan is a Hong Kong-based life science company founded in 2021 at Hong Kong Science and Technology Parks. A spin-off from the Centre for Virology, Vaccinology and Therapeutics, it is among the first companies in the Asia-Pacific region to develop and commercialise a respiratory organoid platform. Leveraging proprietary organoid technology and high-efficiency culture systems, BiomOrgan supports academic, pharmaceutical and biotech partners in accelerating biomedical research, disease modelling, drug screening and therapeutic development.

Learn more about BiomOrgan here.

About InnoHK Centre for Virology, Vaccinology and Therapeutics (CVVT), HKU

CVVT is an R&D centre funded by the InnoHK initiative under the Innovation and Technology Commission (ITC) of the HKSAR Government. Led by Professor Yuen Kwok-yung, the centre brings together international scientific talent to advance the development of respiratory virus vaccines, antimicrobial agents, rapid diagnostics and organoid modelling technologies. It aims to address emerging and re-emerging infectious disease threats by translating research into practical applications to mitigate their impact on public health and the economy.

Learn more about InnoHK Centre for Virology here.